Momelotinib for VEXAS syndrome
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This study tests whether the drug momelotinib can safely reduce inflammation and improve symptoms in people with VEXAS syndrome, a rare genetic condition. Participants will keep taking their usual steroids and may receive momelotinib or a placebo to see if it helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed VEXAS diagnosis with a specific UBA1 gene mutation and current or recent inflammation in at least one organ system.
- You have been taking steroids (like prednisone) for at least 4 weeks, including at least 10 days right before the study starts.
- You are not pregnant or breastfeeding, and if you can become pregnant, you agree to use highly effective birth control.
- You are able to give informed consent and follow the study rules.
- You have not been in the intensive care unit more than once for a VEXAS flare in the past 6 months, and you do not have certain severe health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called arumakimig (MAS825) in people with VEXAS, a rare genetic condition that causes inflammation. The trial checks if the drug helps control symptoms and improve quality of life.
This trial tests a new drug called pacritinib for people with VEXAS syndrome, a rare autoinflammatory condition. The goal is to see if pacritinib can help control symptoms like rashes, joint pain, and low blood counts.
This study aims to find out how common VEXAS syndrome is and how it looks in people over 50 who have unexplained inflammation or blood issues. It helps doctors better recognize and diagnose this rare condition.
This trial tests a drug called momelotinib for people with VEXAS syndrome, a rare inflammatory condition. The goal is to see if momelotinib can reduce symptoms and the need for steroids.
This study looks at how VEXAS syndrome affects your daily life and finances. It aims to understand the challenges you face so doctors can better support you.
This study tests a new gene therapy called ASP2957 in young boys with X-linked myotubular myopathy who are dependent on a ventilator. The goal is to see if it can help improve their breathing and muscle strength.
Hear when a new VEXAS Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.